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Abstract: End-stage kidney disease is a strong risk factor for cardiovascular-specific mortality.
Polyphenol-rich interventions may attenuate cardiovascular disease risk factors; however, this
has not been systematically evaluated in the hemodialysis population. Using the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, the following
databases were searched: Cochrane Library (http://www.cochranelibrary.com/), MEDLINE
(https://health.ebsco.com/products/medline-with-full-text), Embase (https://www.elsevier.com/
solutions/embase-biomedical-research), and CINAHL (https://www.ebscohost.com/nursing/
products/cinahl-databases/cinahl-complete). Meta-analyses were conducted for measures of lipid
profile, inflammation, oxidative stress, and blood pressure. Risk of bias was assessed using the
Cochrane Collaboration Risk of Bias tool and quality of the body of evidence was assessed by the
Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology.
Twelve studies were included for review. Polyphenol-rich interventions included soy, cocoa,
pomegranate, grape, and turmeric. Polyphenol-rich interventions significantly improved diastolic
blood pressure (Mean Difference (MD) −5.62 mmHg (95% Confidence Interval (CI) −8.47, −2.78);
I2 = 2%; p = 0.0001), triglyceride levels (MD−26.52 mg/dL (95% CI−47.22, −5.83); I2 = 57%; p = 0.01),
and myeloperoxidase (MD −90.10 (95% CI −135.84, −44.36); I2 = 0%; p = 0.0001). Included studies
generally had low or unclear risks of bias. The results of this review provide preliminary support for
the use of polyphenol-rich interventions for improving cardiovascular risk markers in haemodialysis
patients. Due to the limited number of studies for individual polyphenol interventions, further
studies are required to provide recommendations regarding individual polyphenol intervention
and dose.
Keywords: polyphenol; dialysis; cardiovascular; review; meta-analysis; oxidative stress; inflammation;
blood pressure; pomegranate; cocoa; soy; turmeric
1. Introduction
End-stage kidney disease (ESKD) is a major health burden worldwide, with over 2 million people
estimated to be receiving renal replacement therapy [1]. Among those with ESKD, cardiovascular
disease (CVD) accounts for almost 50% of all deaths, most commonly sudden cardiac death [2].
Many factors are known to influence the elevated CVD risks in ESKD, including high blood pressure,
dyslipidaemia and high levels of oxidative stress [3,4]. The uraemic state, which causes increased
production of pro-inflammatory cytokines and promotes oxidative stress, may trigger the onset
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and progression of atherosclerosis and CVD [5]. While adequate dialysis therapy ameliorates the
accumulation of uremic toxin and pro-inflammatory cytokines, the dialysis process itself can induce
a chronic state of inflammation [6]. This can be further compromised by the loss of key antioxidants
during haemodialysis [7], which further exacerbates inflammation and therefore, increases the risk of
CVD in dialysis patients.
Lifestyle modification, including adherence to a cardio-protective diet may provide potential
improvements in CVD risk factors in dialysed ESKD patients [8]. However, common limitations to
developing nutrition management plans in dialysis, particularly haemodialysis, arise when attempting
to implement a cardio-protective diet [9]. Many nutrient restrictions placed on haemodialysis patients
have the knock-on effect of limiting antioxidant vitamins (e.g., ascorbic acid, tocopherols), minerals
(e.g., selenium), and various non-nutritive polyphenols, which may be attributable to the commonly
higher levels of potassium in nutrient-rich fruit and vegetables [10]. Therefore, a low risk dietary
intervention which may improve intake of potentially cardioprotective compounds may improve CVD
outcomes in the haemodialysis patient.
A healthy dietary pattern, such as the Mediterranean and Dietary Approaches to Stop
Hypertension (DASH) diet, are associated with reduced risk of death in renal disease [8,11]. One of the
proposed mechanisms of mediated risk is through higher intake of fruits and vegetables, which are
inherently cardio-protective due to their higher levels of dietary fibre, antioxidants, and lower renal
acid load [10,11]. In addition, plant-based diets provide an abundant source for a large number of
non-nutrient phytochemicals such as carotenoids and polyphenols [12,13].
Polyphenols, present only in plant-based foods, have been associated with reductions in
cardiovascular disease and related chronic diseases in large observational studies [14–17]. Examples of
food sources of polyphenols include various berries (hydroxybenzoic & hydroxycinnamic acids),
grapes and currants (anthocyanins), onions and kale (flavonols), parsley and celery (flavones),
soy products (isoflavones), and fruit juices (flavanones) [18]. The potential mechanisms of action
responsible for these cardioprotective effects include their antioxidant and anti-inflammatory
properties [19]. Polyphenols may also influence cholesterol levels through modulation of hepatic
cholesterol metabolism [20]. Furthermore, animal studies have demonstrated reductions in blood
pressure after polyphenol consumption that was associated with endothelium-dependent relaxation
and induction of gene expression related to nitric oxide synthase [21].
In haemodialysis supplementation studies, key vitamins have demonstrated improvements in
(non-polyphenol) antioxidant activity, such as Vitamin C [22] and Vitamin E supplementation [23,24].
While other polyphenol-rich interventions have shown promise to control oxidative stress and
ameliorate inflammation in ESKD patients, for example, grape juice powder [25], pomegranate
juice [26], turmeric [27], and cocoa flavanols [28].
To date, the effects of polyphenol-rich interventions on CVD risk markers is mixed and no
systematic review has specifically evaluated nor pooled the effect of polyphenols on CVD outcomes in
dialysis patients. Therefore, the aim of this review was to systematically evaluate the literature from
existing randomised controlled trials on polyphenol-rich interventions (food and products) and how it
affects CVD markers in haemodialysis populations.
2. Methods
2.1. Literature Search
This review is written in accordance with the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines [29]. Relevant studies were identified through a systematic
search of the Cochrane Library, MEDLINE (via Scopus), Embase, and CINAHL databases for articles
published since journal inception up to the 29 June 2017. Search terms (including mapping to
appropriate MeSH terms where appropriate) described major polyphenol classes (‘polyphenol’;
‘phenol’; ‘flavonoid’; ‘flavone’; ‘flavonol*’; ‘isoflavon*’; ‘hydroxycinnamic’; ‘hydroxybenzoic’) and
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common polyphenol-rich foods (‘Juice’; ‘wine’, ‘tea’; ‘olive’; ‘cacao’; ‘berry’; ‘herb’; ‘spice’; ‘plant’; ‘soy’;
‘flax’; ‘nut’; ‘mint’); in combination with keywords relating to dialysis (‘dialysis’; ‘end-stage renal’;
‘end-stage kidney’; haemodialysis’; ‘peritoneal’; ‘renal failure’; ‘kidney failure’; ESKD’ referring to End
Stage Kidney Disease; ‘ESRD’ referring to End Stage Renal Disease).
Studies were eligible for inclusion if they (1) used a double blind, randomized, placebo-controlled
trial study design; (2) had no concurrent intervention; (3) examined the effect of a polyphenol-rich
intervention on CVD outcomes (e.g., lipid profile, blood pressure, oxidative stress); and (4) recruited
haemodialysis patients only. Other ESKD populations were excluded, in an attempt to keep the study
population homogenous. We used the Phenol-Explorer 3.6 database to characterize and inform our
decision on known polyphenol-rich interventions [30,31].
2.2. Data Extraction
The screening of articles was independently conducted by two review authors (J.K. and W.M.), with
disagreements in judgement resolved by consensus or third reviewer (S.M.). Relevant articles titles and
abstracts were initially screened. If deemed potentially eligible, studies were selected for full text review.
Data was extracted from relevant studies using the following parameters: author/date, study design,
sample size, total study period, population characteristics (including age, gender and co-morbidities),
intervention characteristics (including type of polyphenol, dose and duration of exposure), length of
follow up, and country of origin. For all included studies, mean, standard deviation (SD), standard error
or 95% confident intervals (CI) for all pre-specified outcome data that were reported at baseline and
follow-up were extracted for analysis if a significant difference was reported. Data was extracted by one
reviewer (S.M.) and checked for accuracy by a second reviewer (S.N.).
2.3. Assessment of Study and Evidence Quality
Bias assessment was preformed based on the Cochrane Risk of Bias tool [32]. This tool provides
criteria for assessing the quality of the included studies. All studies were included in the review
regardless of bias rating. A score of ‘high’ indicated a high risk of all bias categories. A score of
‘unclear’ was given when information available was inadequate to correctly comment. A score of ‘low’
indicated low risk of all forms of bias and was the most desirable outcome.
The certainty in the body of evidence for each CVD outcome category was assessed using
the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) assessment
tool [33] Certainty in the body of evidence was informed by considering risk of bias, inconsistency,
indirectness, imprecision, publication bias, effect size, dose-response and plausible confounding. Based
on the pooled or combined data across studies informing these considerations, the certainty in the
body of evidence was conserved as very low, low, moderate or high [34]. Determination of the GRADE
level of evidence was determined independently by two reviewers (S.M. and J.K.), with disagreements
managed by consensus and discussion with a third reviewer (W.M.).
2.4. Data Analysis
The overall treatment effect on primary and secondary outcomes was calculated as the difference
between the intervention and comparison groups’ from change scores from baseline to the end of
follow-up, or end of intervention values, permitting no significant differences observed at baseline
between groups.
Quantitative analysis was conducted for sufficiently homogeneous and adequately reported
outcome measures by pooling data into Review Manager (Version 5.3, The Cochrane Collaboration
2014) for meta-analysis using raw data. The appropriate variance from each individual study was
used, either as the SD or calculated from the standard error of the mean (SEM) or 95% CI. Studies that
reported on Median and Inter-Quartile-Ranges were assumed to not be normally distributed data and
therefore not included in the meta-analysis. Meta-analysis was performed using the DerSimonian and
Laird random-effects model [35]
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The I2 statistic was used to assess the inconsistencies between studies and describe the percentage
of variability in effect and data was checked using the fixed-effect model to ensure robustness and
susceptibility to potential outliers. Heterogeneity was considered substantial if the I2 statistic was
≥50%. A statistically significant (p < 0.05) result was considered evidence of an effect.
3. Results
3.1. Study Selection
As shown in Figure 1, the literature search identified 3521 citations after the removal of duplicates.
Initial screening identified 50 papers as potentially relevant for full text review. From this, 39 studies
were excluded as they did not meet the inclusion criteria. Hand searching identified 1 additional study
for inclusion, leaving 12 total studies included in the review.
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3.2. Study Characteristics
Table 1 provides a summary of the study designs of included studies. The total sample size of the
included studies was 520 participants, with individual study sample sizes ranging from 27 to 101 participants.
All studies used a double-blind, randomized placebo-controlled parallel study design.
3.3. Interventions
A variety of interventions were investigated including pomegranate juice (standardized to
0.7 mmol/L polyphenols) [26,36,37], pomegranate extract (standardized to 600–755 mg gallic acid
equivalents), cacao (900 mg cocoa-flavanols) [28], turmeric (22.1 mg curcumin) [27,38], grape (500 mg
total polyphenols) [25], green tea (455 mg total catechins) [39], and soy (26–54 mg isoflavones)
(Table 2) [40–43]. The duration of the study interventions varied from an acute, one day study [26]
to 12 months [36,37]. Interventions were delivered in a juice [26,36,37]; a fortified jelly [25]; drink,
cereal or protein bar [40]; powder [28,41–43]; or capsules [27,38,44]. Most studies required participants
to consume the intervention each day of the study duration with the exception of one acute study
where participants consumed pomegranate juice once during the first hour of a haemodialysis session
and two long term studies where the intervention was given three or four times per week [26,37,43].
One study reported results as Median and Inter-Quartile-Ranges and were assumed to not be normally
distributed data and not included in the meta-analysis [40].
Table 1. Summary of included studies.
Study Setting Study Design Population
Soy protein (contains isoflavones)
Fanti et al. 2006 [40]
• USA
• Unknown number
and type of
recruitment sites
• Data collected:
dates not specified
• Two-arm parallel,
placebo-controlled,
double-blind
randomised trial
• Allocation method:
random allocation 2:1
• ESRD on haemodialysis. Primary
disease 44% DM, 36% HTN,
20% other.
• n = 32 participants; n = 19 IG;
n = 13 CG. Attrition: 22% (n = 15
IG; n = 10 CG)
• Mean age 61.0 ± 2.9 years;
40% female.
Chen et al. 2005 [42]
• Taiwan
• 1 hemodialysis
centre, from a
general hospital.
• Data collected:
dates not specified
• Two-arm parallel,
placebo-controlled,
double-blind
randomised trial
• Allocation method:
random allocation 1:1
• ESRD on haemodialysis. Primary
diseases not described.
• n = 42 participants; n = 18 IG;
n = 19 CG (post attrition
numbers). Attrition: 12%.
• Participants divided into
normolipidemic (n = 10 CG; n = 9
IG) and hyperlipidemic (n = 9
CG; n = 10 IG)
• Mean age 59–66 ± 9–13 years;
92% female.
Chen et al. 2006 [41]
• Taiwan
• 1 hemodialysis
centre, from a
general hospital.
• Data collected:
dates not specified
• Two-arm parallel,
placebo-controlled,
double-blind
randomised trial
• Allocation method:
random allocation 1:1
• ESRD on haemodialysis and all
with hypercholesterolaemia.
Primary diseases not described.
• n = 29 participants; n = 18 IG;
n = 19 CG (post attrition
numbers). Attrition: 11%.
• Participants divided into
normolipidemic (n = 13 CG;
n = 13 IG) and hyperlipidemic
(n = 9 CG; n = 10 IG)
• Mean age 58–59 ± 11–12 years;
27% female.
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Table 1. Cont.
Study Setting Study Design Population
Soy protein (contains isoflavones)
Siefker & DiSilvestro
2006 [43] • USA
• 2 hemodialysis
centres, from 2
general hospitals.
• Data collected:
dates not specified
• Two-arm parallel,
placebo-controlled,
double-blind
randomised trial
• Allocation method:
random allocation 1:1
• ESRD on haemodialysis and all
with hypercholesterolaemia.
Primary diseases not described.
• n = 20 participants; n = 8 IG; n = 9
CG (post attrition numbers).
Attrition: 15%.
• Mean age 20 years (range 27–77);
59% female.
Grape (contains various polyphenols)
Janiques et al. 2014
[25] • Brazil
• 1 nephrology centre
• Data collected:
dates not specified
• Two-arm parallel,
placebo-controlled,
double-blind
randomised trial
• Allocation method:
random allocation 1:1
• ESRD on haemodialysis. Primary
diseases not described.
• n = 34 participants; n = 17 IG;
n = 17 CG. Attrition: 6% (n = 16
IG; n = 16 CG).
• Mean age 52.7–53.0 ± 9.8–13.7
years; 44% female.
Turmeric (contains curcuminoids)
Pakfetrat et al. 2014
[38] • Iran
• 1
haemodialysis centre
• Data
collected: 2011–2012
• Two-arm parallel,
placebo-controlled,
double-blind
randomised trial
• Allocation method:
random allocation 1:1
• ESRD on haemodialysis, all with
uremic pruritus. Primary
diseases not described.
• n = 100 participants; n = 50 IG;
n = 50 CG. Attrition: 0%.
• Mean age 51.0–55.6 ± 14.7–16.6
years; 40% female.
Pakfetrat et al. 2015 a
[27] • Iran
• 1
haemodialysis centre
• Data collected:
dates not specified
• Two-arm parallel,
placebo-controlled,
double-blind
randomised trial
• Allocation method:
random allocation 1:1
• ESRD on haemodialysis, all with
uremic pruritus. Primary
diseases: 35% DM, 33% HTN.
• n = 50 participants; n = 50 IG;
n = 50 CG. Attrition: 4%.
• Mean age 47–52 ± 15 years;
45% female.
Cocoa (contains flavanols)
Rassaf et al. 2016 [28]
• Germany
• 1 renal centre
• Data
collected: 2012–2013
• Two-arm parallel,
placebo-controlled,
double-blind
randomised trial
• Allocation method:
random allocation 1:1
• ESRD on haemodialysis, all with
uremic pruritus. Primary
diseases: 32% HTN, 23% DM,
19% GN, 26% other.
• n = 52 participants; n = 26 IG;
n = 26 CG. Attrition: 6% (n = 24
IG; n = 25 CG).
• Mean age 65 ± 13 years;
26% female.
Pomegranate (Phenolic acids & Flavanoids)
Shema-Didi et al.
2012 [37] • Israel
• 1 dialysis centre in
a hospital
• Data collected:
dates not specified.
• Two-arm parallel,
placebo-controlled,
double-blind
randomised trial
• Allocation method:
random allocation 2:1
• ESRD on haemodialysis. Primary
diseases: 64% DM, 60% CVD.
• n = 101 participants; n = 66 IG;
n = 35 CG. Attrition: 34% (n = 41
IG; n = 26 CG).
• Mean age 66–68 ± 11–13 years;
45% female.
Shema-Didi et al.
2014 [36]
As per Shema-Didi et al.
2012 [37]
Shema-Didi et al. 2012 [37] Shema-Didi et al. 2012 [37]
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Table 1. Cont.
Study Setting Study Design Population
Pomegranate (Phenolic acids & Flavanoids)
Shema-Didi et al.
2013 [26] • Israel
• 1 dialysis centre in
a hospital
• Data collected:
dates not specified.
• Two-arm parallel,
placebo-controlled,
double-blind
randomised trial.
• Allocation method:
random allocation 2:1
• ESRD on haemodialysis,
receiving an iron transfusion
during a single haemodialysis
session. Primary diseases: 60%
DM, 51% CVD. Others
not described.
• n = 27 participants; n = 17 IG;
n = 10 CG. Attrition: N/A
• Mean age 65–67 ± 11–13 years;
40% female.
Wu et al. 2015 [44]
• USA
• Unknown number
of dialysis clinics in
two cities
• Data collected:
dates not specified.
• Two-arm parallel,
placebo-controlled,
double-blind
randomised trial
• Allocation method:
random allocation 1:1
• ESRD on haemodialysis. Primary
diseases: 49% HTN, 36% DM.
Others not described.
• n = 33 participants; n = 16 IG;
n = 17 CG. Attrition: 19% (n = 13
IG; n = 14 CG).
• Mean age 53–56 ± 3 years;
39% female.
CVD, Cardiovascular Disease; CG, control group; DM, Diabetes Mellitus; HTN, hyptertension; IG, intervention group;
N/A, Not Applicable; a It is unclear if the sample and study is the same as that described in Pakfetrat et al. 2014 [38].
The samples appear to be the same; where Pakfetrat et al. [27] excluded some participants after recruitment, which could
explain slight differences in sample characteristics. However, Pakfetrat et al. 2015 [27] does not refer to the earlier study
at all, and therefore it is not clear.
Table 2. Included Study Intervention Details and Results.
Study Intervention Results
Soy protein (contains isoflavones)
Fanti et al. 2006 [40] Intervention: Isoflavone-containing
soy-based a protein powder mixed into a
drink (54 mg isoflavones), a protein bar
(26 mg isoflavones) or cereal product (26 mg
isoflavones).
Comparator: Isoflavone-free milk-based
protein powder mixed into a drink, a protein
bar or a cereal product. Energy, protein,
CHO, fat, Na and K intake equal to
intervention product.
Dose: one supplement item daily (powder
3 times per week; bar or cereal 4 times per
week).
Duration: 8-weeks.
Pro-inflammatory markers: 8-weeks
post-baseline:
Serum CRP
• IG median 9.7 (IQR: 5.2–20.7 mg/L)
• CG median 17.5 (IQR: 9.1–40.7 mg/L)
• p > 0.05 between groups
Ex-vivo peripheral blood IL-6—unstimulated
• IG median 10.3 (IQR: 8.0–14.0 pg/mL)
• CG median 32.7 (IQR: 14.5–86.4 pg/mL)
• p > 0.05 between groups
Ex-vivo peripheral blood IL-6—simulated with
lipopolysaccharide
• IG median 3249.0 (IQR: 1288.5–4024.4
pg/mL)
• CG median 2076.3 (IQR: 524.9–3268.2
pg/mL)
• p > 0.05 between groups
Ex-vivo peripheral blood TNF-α—unstimulated
• IG median 7.5 (IQR: 6.6–8.1 pg/mL)
• CG median 9.0 (IQR: 7.3–17.6 pg/mL)
• p > 0.05 between groups
Ex-vivo peripheral blood TNF-α—simulated with
lipopolysaccharide
• IG median 790.9 (IQR: 445.4–1120.1 pg/mL)
• CG median 504.6 (IQR: 257.1–975.3 pg/mL)
• p > 0.05 between groups
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Table 2. Cont.
Study Intervention Results
Soy protein (contains isoflavones)
Chen et al. 2005 [42] Intervention: 30 g isolated soy protein
(36.3 mg isoflavone content; as reported in
Chen et al. 2006 [41]) fortified with calcium,
mixed with 200 mL fluid.
Comparator: 30 g milk protein, with
equivalent amounts of calcium, energy,
carbohydrate and fat; mixed with 200 mL
fluid.
Dose: one supplement daily
Duration: 12-weeks.
Normolipidemic Subjects—Lipid profile:
12-weeks post-baseline:
Fasting serum TG:
• IG µ123.6 ± 31.3 mg/dL
• CG µ130.2 ± 26.9 mg/dL
• p > 0.05 between groups
Fasting serum total cholesterol:
• IG µ106.4 ± 30.9 mg/dL
• CG µ135.7 ± 27.8 mg/dL
• p > 0.05 between groups
Fasting serum HDL-C:
• IG µ36.5 ± 11.2 mmol/L
• CG µ37.8 ± 6.6 mmol/L
• p > 0.05 between groups
Fasting serum LDL-C:
• IG µ97.8 ± 22.8 mmol/L
• CG µ100.7 ± 27.1 mmol/L
• p > 0.05 between groups
Hyperlipidemic Subjects—Lipid profile:
12-weeks post-baseline:
Fasting serum TG:
• IG µ185.7 ± 62.6 mg/dL; p < 0.05 decreased
since baseline (µ333.2 ± 114.6 mg/dL)
• CG µ307.9 ± 132.4 mg/dL
• p < 0.05 between groups
Fasting serum total cholesterol:
• IG µ216.7 ± 28.1 mg/dL; p < 0.05 decreased
since baseline (µ265.7 ± 28.2 mg/dL)
• CG µ257.7 ± 23.7 mg/dL
• p < 0.05 between groups
Fasting serum HDL-C:
• IG µ39.1 ± 7.6 mg/dL; p < 0.05 increased
since baseline (µ33.3 ± 10.1 mg/dL)
• CG µ36.8 ± 5.7 mg/dL
• p > 0.05 between groups
Fasting serum LDL-C:
• IG µ111.0 ± 36.1 mg/dL; p < 0.05 decreased
since baseline (µ150.6 ± 28.2 mg/dL)
• CG µ139.1 ± 29.0 mg/dL
• p > 0.05 between groups
Chen et al. 2006 [41] Supplement: 30 g isolated soy protein
(36.3 mg isoflavone content) fortified with
calcium, mixed with 200 mL fluid.
Comparator: 30 g milk protein, with
equivalent amounts of protein, calcium,
energy, carbohydrate and fat; mixed with
200 mL fluid.
Dose: one supplement daily
Duration: 12-weeks.
Lipid profile: 12-weeks post-baseline:
Fasting serum TG:
• IG µ1.77 ± 0.38 mmol/L
• CG µ1.88 ± 0.29 mmol/L
• p > 0.05 between groups
Fasting serum total cholesterol:
• IG µ5.76 ± 0.89 mmol/L
• CG µ6.59 ± 0.97 mmol/L
• p < 0.05 between groups
Fasting serum HDL-C:
• IG µ1.03 ± 0.19 mmol/L
• CG µ0.98 ± 0.13 mmol/L
• p > 0.05 between groups
Fasting serum LDL-C:
• IG µ3.56 ± 0.78 mmol/L; p < 0.05 decreased
since baseline (µ4.31 ± 1.03 mg/dL)
• CG µ3.98 ± 0.61 mmol/L
• p > 0.05 between groups
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Table 2. Cont.
Study Intervention Results
Soy protein (contains isoflavones)
Siefker & DiSilvestro
2006 [43]
Intervention: soy protein powder (52 mg
isoflavone content) mixed with fluid,
artificial chocolate flavoured.
Comparator: whey protein powder mixed
with fluid, artificial chocolate flavoured.
Dose: one supplement 4 times per week
Duration: 4-weeks.
Oxidative stress markers: 4-weeks post-baseline:
Oxidized LDL-C:
• Data not reported—presented
graphically only.
• p < 0.05 IG decrease since baseline.
• Average change p < 0.05 between groups
(IG 31.02% vs. CG 11.12%).
Pro-inflammatory markers: 4-weeks
post-baseline:
TNF-α:
• IG µ4.1 ± 0.6 pg/mL
• CG µ5.7 ± 0.8 pg/mL
• p > 0.05 between groups
Plasma CRP:
• IG µ11701 ± 4741 ng/mL
• CG µ4095 ± 1952 ng/mL
• p > 0.05 between groups
8-iso-prostaglandin F2α:
• IG µ490.0 ± 185.1 pg/mL
• CG µ442.2 ± 56.7 pg/mL
• p > 0.05 between groups
Grape (contains various polyphenols)
Janiques et al. 2014 [25] Intervention: 12 g (500 mg total polyphenols)
grape powder mixed into grape jelly.
Comparator: grape jelly/placebo.
Dose: 1 tablespoon of jelly daily consumed
in the afternoon.
Duration: 5-weeks.
Anti-inflammatory markers: Not clear when
measured; assumed to be measured at end of
treatment (5-weeks post-baseline):
Plasma GSH-Px:
• IG µ42.0 ± 43.3 nmol/min/mL; p < 0.05
increased since baseline (µ16.5 ± 41.0
nmol/min/mL); p < 0.05 higher at baseline
than CG (IG µ16.5 ± 41.0 vs. CG µ1.0 ± 3.46
nmol/min/mL)
• CG µ17.8 ± 50.3 nmol/min/mL
• p > 0.05 between groups
Pro-inflammatory markers: Not clear when
measured; assumed to be measured at end of
treatment (5-weeks post-baseline):
Plasma CRP:
• IG µ2.7 ± 0.3 mg/dL
• CG µ2.8 ± 0.2 mg/dL; p < 0.05 increased
since baseline (µ2.6 ± 0.3 mg/dL)
• p > 0.05 between groups
Turmeric (contains curcuminoids)
Pakfetrat et al. 2014 [38] Intervention: capsule of 500 mg (22.1 mg
active ingredient curcumin, a polyphenol)
turmeric powder
Comparator: capsule of starch/placebo.
Dose: 3 capsules per day, one with each
main meal.
Duration: 8-weeks
Pro-inflammatory markers: Not clear when
measured; assumed to be measured at end of
treatment (8-weeks post-baseline):
High-sensitivity CRP:
• IG µ7.0 ± 8.9 mg/L; p < 0.003 decrease
since baseline (µ10.8 ± 9.7 mg/L)
• CG µ9.6 ± 9.5 mg/L
• p > 0.05 between groups
• p = 0.012 Mean change different between
groups (IG −µ0.8 ± 2.6 mg/L vs. CG µ0.4
± 8.7 mg/L)
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Turmeric (contains curcuminoids)
Pakfetrat et al. 2015 [27] Intervention: capsule of 500 mg (22.1 mg
active ingredient curcumin, a polyphenol)
turmeric powder
Comparator: capsule of starch/placebo.
Dose: 3 capsules per day, one with each
main meal.
Duration: 8-weeks
Oxidative stress: 8-weeks post-baseline:
Red blood cell catalase (CAT):
• IG µ127.30 ± 19.55 kilounits/g Hb;
p < 0.0001 increase since baseline (µ107.78
± 14.28 kilounits/g Hb)
• CG µ141.14 ± 22.72 kilounits/g Hb;
p < 0.0001 increase since baseline (µ109.11
± 11.78 kilounits/g Hb)
• Ratio of change significantly between
groups (IG: µ0.1 ± 0.2 vs. CG: µ0.3 ± 0.2
kilounits/g Hb; p = 0.039)
Red blood cell glutathione reductase (GR):
• IG µ35.4 ± 18.7 units/g Hb
• CG µ37.7 ± 19.8 units/g Hb
• p > 0.05 between groups
Red blood cell glutathione peroxidase:
• IG µ58.2 ± 46.3 units/g Hb; p < 0.001
increase since baseline (µ25.6 ± 26.1
units/g Hb)
• CG µ56.2 ± 28.2 units/g Hb; p < 0.001
increase since baseline (µ28.6 ± 22.1
units/g Hb)
• p > 0.05 between groups
Malondialdehyde (MDA):
• IG µ6.0 ± 2.4 nmol/mL; p < 0.001 decrease
since baseline (µ8.6 ± 1.4 nmol/mL)
• CG µ7.5 ± 1.1 nmol/mL; p < 0.001 decrease
since baseline (µ7.5 ± 2.5 nmol/mL)
• Ratio of change significantly between
groups (IG: µ0.2 ± 0.2 vs. CG: µ0.1 ± 0.1
nmol/mL; p = 0.040)
Cocoa (contains flavanols)
Rassaf et al. 2016 [28] Intervention: 450 mg cocoa-flavanol
containing low-energy fruit-flavoured
powder to be mixed as a drink.
Comparator: low-energy fruit-flavoured
powder to be mixed as a drink, matched for
energy, protein, CHO, micronutrients,
theobromine and caffeine.
Dose: Two sachets (900 mg cocoa-flavanols)
daily
Duration: 30 days
Haemodynamics markers: 30-days
post-baseline:
Flow-mediated vasodilation of the brachial artery:
• IG µ3.4 ± 0.9%; p < 0.001 increase since
baseline (µ3.9 ± 0.8%)
• CG µ3.5 ± 0.7%
• p < 0.001 between groups
Pulse wave velocity:
• IG µ11.0 ± 0.9 m/s
• CG µ12.0 ± 1.1 m/s
• p = 0.32 between groups
Carotid intima-media thickness:
• IG µ0.81 ± 0.02 mm
• CG µ0.79 ± 0.02 mm
• p = 0.28 between groups
Blood pressure
Systolic blood pressure:
Acute
• IG µ122 ± 21 mmHg;
• CG µ124 ± 18
• p = 0.03 between groups
Diastolic blood pressure:
• IG µ66 ± 1.0 mmHg;
• CG µ72 ± 9
• p = 0.04 between groups
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Cocoa (contains flavanols)
Chronic
Diastolic blood pressure:
• IG µ69 ± 11 mmHg; p < 0.004 decrease
since baseline (µ73 ± 12 mmHg)
• CG µ73 ± 13
• p = 0.03 between groups
Acute on chronic
Systolic blood pressure:
• IG µ134 ± 29 mmHg;
• CG µ133 ± 24
• p = 0.60 between groups
Diastolic blood pressure:
• IG µ68 ± 11 mmHg;
• CG µ72 ± 10
• p = 0.86 between groups
Pro-inflammatory markers: 30-days
post-baseline:
IL-6:
• IG µ3.3 ± 0.4 pg/mL
• CG µ3.3 ± 0.6 pg/mL
• p > 0.05 between groups
CRP:
• IG µ0.7 ± 0.2 mg/dL
• CG µ0.8 ± 0.5 mg/dL
• p = 0.77 between groups
AGE CML:
• IG µ3438 ± 310 ng/L
• CG µ3189 ± 324 ng/L
• p = 0.35 between groups
Oxidative stress markers: At day 30:
Oxidized LDL-C:
• IG µ51.2 ± 3.6 units per L
• CG µ50.1 ± 1.8 units per L
• p > 0.05 between groups
Pomegranate (Phenolic acids & Flavonoids)
Shema-Didi et al. 2012
[37]
Intervention: Commercial pomegranate
juice (0.7 mmol polyphenols/100 mL juice).
Comparator: Placebo juice containing
artificial pomegranate extract, confirmed no
polyphenol content.
Dose: 100 mL, three times per week.
Duration: 12-months.
Oxidative stress: 12-months post-baseline:
CD11b:
• IG µ20.3 ± 7.4 mean fluorescence intensity
• CG µ27.1 ± 11.2 mean fluorescence intensity
• p = 0.002 between groups
Serum myeloperoxidase (MPO):
• IG µ88.9 ± 62.0 ng/mL
• CG µ181.2 ± 152.9 ng/mL
• p = 0.002 between groups
Serum advanced oxidation protein products (AOPP):
• IG µ151.2 ± 39.9 µM
• CG µ177.2 ± 49.7 µM
• p = 0.005 between groups
Serum Oxidised fibrinogen:
• IG µ0.86 ± 0.26 nmol
carbonyls/mg fibrinogen
• CG µ1.03 ± 0.34 nmol
carbonyls/mg fibrinogen
• p = 0.03 between groups
Serum Malondialdehyde (MDA):
• IG µ3.8 ± 1.3 µM
• CG µ6.9 ± 2.6 µM
• p < 0.001 between groups
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Pomegranate (Phenolic acids & Flavonoids)
Pro-inflammatory markers: 12-months
post-baseline:
Serum IL-6:
• IG µ4.1 ± 2.8 pg/mL
• CG µ7.5 ± 4.5 pg/mL
• p < 0.001 between groups
Serum TNF-α:
• IG median 3.9 (IQR: 1.6 pg/mL)
• CG median 6.7 (IQR: 6.8 pg/mL)
• p = 0.03 between groups
Haemodynamics: 12-months post-baseline:
Common carotid intima-media thickness:
• Data not reported, only percent of
participants with improvements or declines.
• Data not reported, only percent of
participants with improvements or declines.
Shema-Didi et al. 2014
[36]
Shema-Didi et al. 2012 [37] Haemodynamics markers: 12-months
post-baseline:
Systolic blood pressure:
• IG µ135.7 ± 21.3 mmHg; p < 0.05 decrease
since baseline (µ145.6 ± 21.9 mmHg)
• CG µ135.6 ± 27.7 mmHg
• p = 0.96 between groups
Systolic blood pressure >140 mmHg at baseline:
• IG µ144.0 ± 16.9 mmHg; p < 0.05 decrease
since baseline (µ157.8 ± 12.9 mmHg)
• CG µ157.8 ± 10.3 mmHg
• p = 0.12 between groups
Diastolic blood pressure:
• IG µ67.7 ± 13.8 mmHg
• CG µ63.8 ± 20.4 mmHg
• p = 0.38 between groups
Pulse pressure:
• IG µ68.0 ± 16.6 p < 0.05 increase since
baseline (µ74.6 ± 19.5 mmHg)
• CG µ68.8 ± 14.2 mmHg
• p = 0.84 between groups
Lipid profile: 12-months post-baseline:
LDL-C:
• IG µ100.0 ± 33.1 mg/dL
• CG µ94.3 ± 27.2 mg/dL
• p = 0.39 between groups
Total-C:
• IG µ167.3 ± 43. mg/dL
• CG µ165.1 ± 35.8 mg/dL
• p = 0.79 between groups
HDL-C:
• IG µ36.8 ± 10.8 mg/dL; p < 0.05 increase
since baseline (µ33.1 ± 9.5 mg/dL)
• CG µ34.3 ± 15.4 mg/dL
• p = 0.40 between groups
HDL-C ≤40 mg/dL at baseline:
• IG µ33.6 ± 7.5 mg/dL; p < 0.05 increase
since baseline (µ29.7 ± 5.7 mg/dL)
• CG µ27.6 ± 11.6 mg/dL
• p = 0.03 between groups
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TG:
• IG µ167.3 ± 86.3 mg/dL; p < 0.05 increase
since baseline (µ183.6 ± 101.6 mg/dL)
• CG µ206.1 ± 109.4 mL/dL
• p = 0.05 between groups
TG ≥200 ng/dL at baseline:
• IG µ237.4 ± 102.5 mg/dL; p < 0.05 increase
since baseline (µ310.1 ± 87.8 mg/dL)
• CG µ320.4 ± 56.8 mg/dL
• p = 0.008 between groups
Shema-Didi et al. 2013
[26]
Intervention: Commercial pomegranate
juice (0.7 mmol polyphenols/100 mL juice).
Comparator: Placebo juice containing
artificial pomegranate extract, confirmed no
polyphenol content.
Dose: 100 mL
Duration: Once during the first hour of a
haemodialysis session.
Oxidative stress markers: At the end of the
dialysis session:
Serum myeloperoxidase (MPO):
• IG µ69.4 ± 74.4 ng/mL
• CG µ152.9 ± 128.4 ng/mL; p = 0.04
increased since before dialysis session
(µ95.7 ± 68.8 ng/mL)
• p = 0.04 between groups
Serum advanced oxidation protein products (AOPP):
• IG µ158.1 ± 55.1 µM
• CG µ217.5 ± 80.8 µM; p = 0.03 increased
since before dialysis session (µ146.0 ±
19.3 µM)
• p = 0.04 between groups
Pro-inflammatory markers: At the end of the
dialysis session:
Serum polymorphonuclear leukocytes (PMNLs):
• IG µ4.4 ± 1.7 ×103/UL
• CG µ4.3 ± 2.6 ×103/UL; p = 0.03 decreased
since before dialysis session (µ5.0 ± 2.8
×103/UL)
• p = 0.96 between groups
Wu et al. 2015 [44] Intervention: 1000 mg capsule of purified
pomegranate polyphenol extract with
600–755 mg gallic acid equivalents.
Comparator: Noncaloric placebo capsule not
further described.
Dose: 1 capsule daily
Duration:6-months
Haemodynamics markers: 6-months
post-baseline:
Systolic blood pressure:
• IG µ133 ± 11.5 mmHg;
• CG µ133 ± 8.2 mmHg
• p < 0.05 between groups (improvement in
IG compared with CG over time)
Diastolic blood pressure:
• IG µ75 ± 4.4 mmHg
• CG µ74 ± 3.7 mmHg
• p < 0.05 between groups (improvement in
IG compared with CG over time)
Mean arterial pressure:
• IG µ97 ± 5.7 mmHg
• CG µ93 ± 4.6 mmHg
• p < 0.05 between groups (improvement in
IG compared with CG over time)
Carotid intima-media thickness:
• IG µ0.76 ± 0.04 mm
• CG µ0.74 ± 0.06 mm
• p > 0.06 between groups
Aortic pressure wave reflection: Augmentation index
normalised to HR 75 bpm:
• IG µ34.1 ± 5.6%
• CG µ21.1 ± 3.6%
• p > 0.05 between groups
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Aortic pulse wave velocity:
• IG µ11.5 ± 1.6 m/s
• CG µ10.4 ± 1.4 m/s
• p > 0.05 between groups
Oxidative stress markers: 6-months
post-baseline:
Oxygen radical absorbance capacity (ORAC)
• IG µ16,586.9 ± 1827.7 µM
• CG µ17,415.0 ± 1391.3 µM
• p > 0.05 between groups
Advanced oxidation protein products
• IG µ144.4 ± 10.8 µM
• CG µ141.3 ± 13.2 µM
• p > 0.05 between groups
Oxidized LDL-C
• IG µ34.1 ± 6.5 U/L
• CG µ27.8 ± 4.4 U/L
• p > 0.05 between groups
8-hydroxy-2’-deoxyguanosine (8-OHdG):
• IG µ33.1 ± 3.0 ng/mL
• CG µ31.5 ± 2.9 ug/mL
• p > 0.05 between groups
Pro-inflammatory markers: 6-months
post-baseline:
CRP:
• IG µ14.4 ± 4.8 mg/L
• CG µ4.6 ± 1.5 mg/L
• p > 0.05 between groups
IL-6:
• IG µ7.6 ± 1.7 pg/mL
• CG µ7.4 ± 1.4 pg/mL
• p > 0.05 between groups
Lipid profile: 6-months post-baseline:
Total cholesterol:
• IG µ186.0 ± 18.5 mg/dL
• CG µ157.3 ± 17.1 mg/dL
• p > 0.05 between groups
LDL-C:
• IG µ117.5 ± 18.2 mg/dL
• CG µ92.0 ± 16.8 mg/dL
• p > 0.05 between groups
HDL-C:
• IG µ47.6 ± 4.6 mg/dL
• CG µ82.0 ± 16.8 mg/dL
• p > 0.05 between groups
TG:
• IG µ104.3 ± 22.2 mg/dL
• CG µ91.1 ± 20.5 mg/dL
• p > 0.05 between groups
AGE CML, Advanced Glycation End product carboxymethyl lysine; CG, Control Group; CRP, C-Reactive Protein;
GSH-Px, Glutathione peroxidase; Hb, haemoglobin; IL, Interleukin; IG, Intervention Group; HDL-C, High Density
Lipoprotein Cholesterol; LDL-C, Low Density Lipoprotein Cholesterol; TNF-α, Tumour Necrosis Factor Alpha;
Total-C, Total Cholesterol; TG, Triglycerides.
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3.4. Study Results
3.4.1. Oxidative Stress
Seven studies reported measures of oxidative stress [26–28,37,43,44]. A variety of measures
were used to assess oxidative stress including advanced oxidation protein products [26,37,44],
polymorphonuclear leukocyte priming [26,37], oxidized fibrinogen [37], oxidized LDL-C (Low Density
Lipoprotein Cholesterol) [28,43,44] , malondialdehyde (MDA) [27,37], oxygen radical absorbance
capacity (ORAC) assay [44], 8-hydroxy-20-deoxyguanosine (8-OHdG) [44], red blood cell catalase [27],
glutathione reductase [27], glutathione peroxidase [25,27], and myeloperoxidase [26,37].
Pomegranate juice and extract improved markers of oxidative stress in three studies [26,37,44]. Two
studies reported significant reductions in advanced oxidation protein products, polymorphonuclear
leukocyte priming, myeloperoxidase [26,37]. One study reported significant reductions in oxidized
fibrinogen (p = 0.03) and MDA (p < 0.001) [37], and another reported a significant interaction effect (group
× time) for a measure of HDL-C (High Density Lipoprotein Cholesterol; p value not reported) associated
paranoxose-1 activity [44].
Soy supplementation reduced oxidized LDL-C in one study (p < 0.05) [43], and one study reported
turmeric supplementation to improve measures of catalase (p = 0.039) and MDA (p = 0.040) [27].
No other significant between-group differences in measures of oxidative stress were reported.
Meta-analyses reported significant improvements in myeloperoxidase (MD −90.10 (95% CI
−135.84, −44.36); I2 = 0%; p = 0.0001; n = 2 studies; 1 polyphenol-rich intervention; n = 126 participants;
Figure 2). There was insufficient data to conduct a meta-analysis on any other measure of oxidative
stress due to insufficient numbers of common outcomes reported in the included studies.
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Pomegranate extract significantly improved systolic and diastolic blood pressure, and mean
arterial pressure (p < 0.05 reported for all measures) [44]. Cocoa flavanols significantly improved
flow-mediated dilatation (p < 0.001) [28]. No other significant between-group differences were reported.
Meta-analyses reported significant improvements in diastolic blood pressure (MD −5.62 mmHg
(95% CI −8.47, −2.78); I2 = 2%; p = 0.0001; n = 4 studies; 2 polyphenol-rich interventions;
n = 245 participants; Figure 3) but not systolic blood pressure (MD mmHg −10.02 (95% CI −21.39,
1.35); I2 = 66%; p = 0.08; n = 4 studies; 2 polyphenol-rich interventions; n = 193 participants)
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Sensitivity analyses were conducted to determine the effect of individual polyphenol-rich
interventions on systolic and diastolic blood pressure. Pomegranate (−19.22 (−30.94, −7.49)) had a
greater effect on systolic blood pressure compared to cacao (−0.99 (−9.65, 7.67); p = 0.01; Figure 4)
whereas there was no subgroup difference between pomegranate (−9.51 (−20.11, 1.09)) and soy (−4.84
(−8.18, −1.49)) for diastolic blood pressure (p = 0.41; Figure 5).
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3.4.4. Lipid Profiles
Fou stud es rep rted on ch g s to chole terol rofile ( .e., total-C, HDL-C, LDL-C and
triglycerides) following pomegranate [36,44], and soy sup lementation [41,42]. Pomegranate had no
significant between-group differences on participant lipid profiles except for one study that reported
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significant improvements in HDL-C (p = 0.03) and triglycerides (p = 0.008) for a subset of participants
with low HDL-C or high triglycerides, respectively [36]. Soy supplementation improved fasting total
cholesterol (p < 0.05) in one study and another study reported significant improvements on fasting
triglycerides and total cholesterol in a subset of hyperlipidemic participants only (p < 0.05) [41,42].
Meta-analyses reported significant improvements in triglycerides (MD −26.52 mg/dL (95% CI
−47.22, −5.83); I2 = 57%; p = 0.01; n = 4 studies; 2 polyphenol-rich interventions; n = 191 participants;
Figure 6) but no significant difference in total (MD −11.24 mg/dL (95% CI −24.81, 2.34); I2 = 76%;
p = 0.10; n = 4 studies; 2 polyphenol-rich interventions; n = 191 participants), HDL-C (MD 2.38
mg/dL (95% CI −0.05, 4.82); I2 = 23%; p = 0.06; n = 4 studies; 2 polyphenol-rich interventions;
n = 191 participants), and LDL-C (MD mg/dL −3.31 (95% CI −14.45, 7.84); I2 = 43%; p = 0.13; n = 4
studies; 2 polyphenol-rich interventions; n = 191 participants).
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Sensitivity analyses were conducted to determine the effect of individual polyphenol-rich
interventions on lipid markers. Soy had a greater effect on total cholesterol (−26.95 (−47.98, −5.93)
vs. 0.92 (−3.57, 5.41); p = 0.01; Figure 7) and LDL-C (−14.08 (−27.93, −0.22) vs. 5.51 (−3.94, 14.95);
p = 0.02; Figure 8) compared to pomegranate. There were no significant subgroup differences between
soy and pomegranate for HDL-C (1.56 (−1.91, 5.03) vs. 3.16 (−2.23, 8.54), respectively; p = 0.63) and
triglycerides (−20.29 (−54.32, 13.73) vs. −35.42 (−53.63, −17.21), respectively; p = 0.44).
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3.5. Adverse Events
Eight studies provided data on measured adverse events or irregular biochemistry [26,28,37–40,45,46].
Most studies did not report any adverse events during the intervention period. Minor gastrointestinal
symptoms (e.g., constipation or diarrhea) were reported in one study [25] Severity of adverse events was only
reported in one study, which reported one serious adverse event (bleeding) within the intervention group [28].
No study reported a statistical analysis to determine significant differences in adverse event rates between
control and interventions arms. Three studies reported changes in potassium levels with all three studies
reporting no change after grape powder [25], soy [43], and cacao [28].
3.6. Risk of Bias
Risk of bias was low or unclear for most studies in the following domains: detection (11/12 rated
as low) and reporting bias (12/12 rated as low), selection bias (10/13 and 11/12 rated as unclear).
Three studies reported high risks of attrition bias and three studies were determined to have other
risks of bias such as possible or undeclared conflicts of interest (Figure 9).
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3.7. Quality of Evidence
Using the GRADE tool, most outcomes were rated at moderate quality (4/12) or very low (5/12)
quality with inconsistency and imprecision being the most common reasons for downgrading (Table 3).
Of the pooled data with significant findings, there was moderate quality of evidence for the effect on
myeloperoxidase (oxidative stress marker); high quality for the effect on diastolic blood pressure, and
very low quality for the effect on triglycerides.
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Table 3. Grading of Recommendations, Assessment, Development and Evaluation (GRADE) assessment of polyphenol supplementation compared to placebo for
improving cardiovascular risk factors in haemodialysis patients.
Quality Assessment Number of Patients Effect
QualityNumber of
Studies Study Design Risk of Bias Inconsistency Indirectness Imprecision
Other
Considerations Polyphenol Placebo Absolute (95% CI)
Oxidative stress (myeloperoxidase)
2 Randomised trials Not serious Not serious Not serious Serious a Strong effect 82 44 MD 90.1 SD lower (135.8 lower to 44.4lower) MODERATE
Oxidative stress (other markers—not pooled)
5 Randomised trials Not serious serious b Not serious Serious c None - - See comment MODERATE
Inflammation (CRP)
5 Randomised trials Not serious very serious d Not serious Serious e None 96 99
MD 1.9 mg/dL higher (2.2 lower to 6.1
higher) VERY LOW
Inflammation (IL-6)
2 Randomised trials Not serious very serious d Not serious Serious e
Both pomegranate
studies 79 49
MD 1.6 mg/dL lower (5.1 lower to 1.96
higher) VERY LOW
Inflammation (AOPP)
3 Randomised trials Not serious very serious d Not serious Serious e
All pomegranate
studies 96 57
MD 17.7 mg/dL lower (46.5 lower to
11.1 higher) VERY LOW
Diastolic blood pressure
4 Randomised trials Not serious Not serious Not serious Not serious None 133 112 MD 5.6 mmHg lower (8.47 lower to2.78 lower) HIGH
Systolic blood pressure
4 Randomised trials Not serious Serious f Not serious Serious e None 107 86
MD 10 mmHg lower (21.4 lower to 1.4
higher) LOW
Hemodynamic measures (other markers—not pooled)
4 Randomised trials Not serious Serious g Not serious Serious h None - - Not pooled. See Table 2 LOW
Lipid profile (TG)
4 Randomised trials Not serious Serious f Not serious Very serious e None 110 81
MD 26.5 mg/dL lower (47.2 lower to
5.8 lower) VERY LOW
Lipid profile (Total-C)
4 Randomised trials Not serious Very serious d Not serious Very serious e None 110 81
MD 11.2 mg/dL lower (24.8 lower to
2.3 higher) VERY LOW
Lipid profile (HDL-C)
4 Randomised trials Not serious Not serious Not serious Serious e None 110 81 MD 2.4 mg/dL higher (0.1 lower to 4.8higher) MODERATE
Lipid profile (LDL-C)
4 Randomised trials Not serious Not serious Not serious Serious e None 110 81 MD 3.3 mg/dL lower (14.5 lower to 7.8higher) MODERATE
CI: Confidence interval; dL: decilitre; HDL-C, High Density Lipoprotein Cholesterol; LDL-C, Low Density Lipoprotein Cholesterol; MD: Mean difference; Total-C, Total Cholesterol; TG,
Triglycerides. a Two studies were pooled in a meta-analysis for the outcome of myeloperoxidase. The 95%CI for the outcome was substantial (−135 to −44). b Although most measures of
oxidative stress showed improvement from baseline in the intervention group; a number of control groups also showed improvement in this outcome. Therefore, decreasing confidence in
the consistency of results for this outcome. c Although some had narrow measures of variance, other did show substantial imprecision in their measures of variance. d Heterogeneity was
high (>70%). e The 95%CI was substantial. f Heterogeneity was substantial (50–70%). g Studies showed some improvement in mean arterial pressure and flow-mediated dilation; but other
studies found no improvement. No improvement was seen in other measures. h Although individual studies and outcomes did not show significant variance; there is overall a small
number of participants for each outcome as well as combined. This decreases confidence in the precision of the effects.
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4. Discussion
The aim of this systematic literature review was to synthesise results from existing randomized
controlled trials to evaluate the effect of polyphenol-rich interventions on cardiovascular markers
in haemodialysis patients. The results of individual studies included in this review indicate that
polyphenol-rich interventions may improve cardiovascular risk in patients on haemodialysis by
improving various markers of inflammation (i.e., CRP, IL-6, TNF-α), lipid profile (i.e., HDL-C
and triglycerides), blood pressure, and oxidative stress (i.e., advanced oxidation protein products,
polymorphonuclear leukocyte priming, myeloperoxidase, oxidized fibrinogen, catalase, glutathione
peroxidase, and MDA); with varying effect sizes and precision across studies.
Despite individual studies reporting significant improvements, pooled results report no effect
for most outcomes excepting myeloperoxidase, diastolic blood pressure and triglycerides. Only
myeloperoxidase, a measure of oxidative stress, had a large pooled effect size. In addition, using
the GRADE assessment, most outcomes were rated as moderate or very low quality which provides
limited confidence that the effect sizes reported in the existing evidence is representative of the true
effect. The exception is for diastolic blood pressure, which was rated as high quality.
Individual studies that investigated cacao [28], pomegranate [26,36,37,44], turmeric [27,38], and
soy [41,43], reported significant improvements in cardiovascular measures. Sensitivity analyses
indicate that some polyphenol-rich interventions may provide greater improvements in cardiovascular
markers. However, due to the small number of available studies investigating individual interventions
in the haemodialysis population, it is premature to conclude superiority of one polyphenol-rich
intervention over another at this time. In addition, while polyphenol-rich interventions reported
significant improvements in numerous cardiovascular markers, there was little consistency in reported
outcomes between studies that measured the same outcome and/or used the same intervention (e.g.,
blood pressure in [36,37]). Hence, future studies are required to expand the currently limited evidence
base and to address such limitations.
The low baseline levels of some cardiovascular markers may be a possible explanation for the
null findings and/or small effect sizes reported in some included studies and pooled data as it may be
unlikely that further reductions are possible. For example, Janiques et al. [25] reported no significant
difference in CRP; however, reported baseline levels (range: 2.6–2.6 mg/dL) were in the normal range
(<3 mg/dL). In contrast, Paketrat et al. [38] reported significant reductions in CRP in participants that
had CRP levels above the normal range (range: 7.0–10.8 mg/dL). This is also supported by the results
of Wu et al. [44], Shema-did et al. [36], and Chen et al. [42] that reported greater decreases in blood
pressure or cholesterol measures in hypertensive or hyperlipidemic participants, respectively.
Due to the large number of foods that contain appreciable levels of polyphenols [30], the habitual
diet of participants may be a significant influence on study results, if not appropriately controlled for.
Few studies included in this review implemented measures to control for this; however, future studies
may benefit from implementing methods such as recording habitual diet throughout the study through
the use of food diaries and research dietitians as well as educating participants on high polyphenol
foods to avoid during the trial duration.
Few adverse events (predominantly gastrointestinal complains, one significant bleeding event
reported [28]) were reported during the included trials which provide preliminary evidence for
polyphenol-rich interventions being relatively safe within the haemodialysis population. However,
due to the additional dietary restrictions present in this population, close monitoring for adverse events
are required with clinical use and future trials are required to further evaluate their safety. In particular,
although not reported to significantly affect patients in the included studies, consumption of certain
polyphenol-rich food items, such as pomegranate juice, can significantly increase potassium intake
beyond what would be typically advised for dialysis patients and therefore, care should be taken with
people with history of or at higher risks of hyperkalaemia.
A further consideration for future research is to address the poor bioavailability of specific
polyphenols. Resveratrol and curcumin (found in turmeric) [45,46], for example, have been
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demonstrated in pharmacokinetic studies to have poor bioavailability and a short half-life which
has been addressed in several studies by using various methods such as nanoencapsulation, lipid
emulsions, and co-administering active compounds that interact with liver enzymes involved in drug
metabolism [46,47]. Addressing limitations with bioavailability may provide greater treatment efficacy.
A related research area is to elucidate potential inter-individual differences in polyphenol
metabolism as this will inform which patients are likely to benefit from polyphenol-rich interventions.
Individual differences in gastrointestinal microbiota appear to significantly influence the metabolism
of certain polyphenols [48]. For example, the soy isoflavone, daidzein, is metabolised to (S)-equol in
only 25–60% of the population [49]. Metabolism of ellagic acid, found in foods such as pomegranate
and berries, can also be affected by microbiota composition, affecting timing, quantity, and types of
metabolites excreted [50]. The role of microbiota on polyphenol metabolism in patients with kidney
disease may be further complicated due to the possible influence of chronic kidney disease on intestinal
microbiota [51,52].
This review includes studies that have used polyphenol-rich interventions. However, food
interventions are comprised of several bioactive nutritive (e.g., vitamins and mineral) and non-nutritive
compounds (e.g., polyphenols) and therefore, the results of the included studies may have been
influenced by these additional compounds. Future trials that use standardized polyphenol extracts are
recommended to control for the influence of non-polyphenol compounds.
The findings of this study provide preliminary evidence regarding polyphenol-rich interventions;
however, results and conclusions are limited by the heterogeneity of interventions, dosages, and
durations as well as variability in the cardiovascular risk of included participants. Although
polyphenol-rich interventions have reported benefits in non-ESKD patients, considering the inclusion
criteria of this review, generalising results to patients with ESKD or chronic kidney disease who are
not receiving dialysis should be avoided until further studies are conducted. Furthermore, studies
with large sample sizes are required to sufficiently evaluate the adverse events of polyphenol-rich
interventions in this population group.
5. Conclusions
This review evaluated the clinical evidence of various polyphenol-rich interventions for
patients with ESKD receiving haemodialysis from double-blind placebo-controlled randomized trials.
The results of this review provide preliminary support for the use of polyphenol-rich interventions as
part of cardiovascular disease prevention and/or management in haemodialysis patients. At this stage,
no specific polyphenol-rich intervention appears superior, which is likely due to the small number of
available studies, small sample sizes, and lack of control of habitual diet. With this in mind, clinical
recommendations are premature until further evidence addresses these limitations.
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